Identification of an endogenous inhibitor of lymphatic vessel formation provides a glimpse at how lymphatic vessel growth is restrained (pages 1023–1030). The findings might be exploited to lower transplant rejection rates.
References
Albuquerque, R.J.C. et al. Nat. Med. 15, 1023–1030 (2009).
Alitalo, K., Tammela, T. & Petrova, T.V. Nature 438, 946–953 (2005).
Ambati, B.K. et al. Nature 443, 993–997 (2006).
Cursiefen, C. et al. Proc. Natl. Acad. Sci. USA 103, 11405–11410 (2006).
Fuh, G., Li, B., Crowley, C., Cunningham, B. & Wells, J.A. J. Biol. Chem. 273, 11197–11204 (1998).
Patel, S.P. & Dana, R. Semin. Ophthalmol. 24, 135–138 (2009).
Chen, L. et al. Nat. Med. 10, 813–815 (2004).
Cursiefen, C. et al. Invest. Ophthalmol. Vis. Sci. 45, 2666–2673 (2004).
Kerjaschki, D. et al. Nat. Med. 12, 230–234 (2006).
Skobe, M. et al. Am. J. Pathol. 159, 893–903 (2001).
Maruyama, K. et al. J. Clin. Invest. 115, 2363–2372 (2005).
Skobe, M. et al. Nat. Med. 7, 192–198 (2001).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Skobe, M., Dana, R. Blocking the path of lymphatic vessels. Nat Med 15, 993–994 (2009). https://doi.org/10.1038/nm0909-993
Issue Date:
DOI: https://doi.org/10.1038/nm0909-993
- Springer Nature America, Inc.
This article is cited by
-
The role of extracellular matrix in mouse and human corneal neovascularization
Scientific Reports (2019)